Renoprotective Effect of Febuxostat Compared with Allopurinol in Hyperuricemic Chronic Kidney Disease Patients Stage 3 and 4
Elshair, H., Nienaa, Y., Koreen, R., Elkholy, N. (2022). Renoprotective Effect of Febuxostat Compared with Allopurinol in Hyperuricemic Chronic Kidney Disease Patients Stage 3 and 4. EKB Journal Management System, 9(9), 71-105. doi: 10.21608/muj.2022.115662.1086
Heba Selim Elshair; Yasser Ahmed Nienaa; Rana Ibrahim Koreen; Noha M Elkholy. "Renoprotective Effect of Febuxostat Compared with Allopurinol in Hyperuricemic Chronic Kidney Disease Patients Stage 3 and 4". EKB Journal Management System, 9, 9, 2022, 71-105. doi: 10.21608/muj.2022.115662.1086
Elshair, H., Nienaa, Y., Koreen, R., Elkholy, N. (2022). 'Renoprotective Effect of Febuxostat Compared with Allopurinol in Hyperuricemic Chronic Kidney Disease Patients Stage 3 and 4', EKB Journal Management System, 9(9), pp. 71-105. doi: 10.21608/muj.2022.115662.1086
Elshair, H., Nienaa, Y., Koreen, R., Elkholy, N. Renoprotective Effect of Febuxostat Compared with Allopurinol in Hyperuricemic Chronic Kidney Disease Patients Stage 3 and 4. EKB Journal Management System, 2022; 9(9): 71-105. doi: 10.21608/muj.2022.115662.1086

Renoprotective Effect of Febuxostat Compared with Allopurinol in Hyperuricemic Chronic Kidney Disease Patients Stage 3 and 4

Medicine Updates
Article 8, Volume 9, Issue 9, April 2022, Page 71-105  XML PDF (1.37 MB)
Document Type: Original Article
DOI: 10.21608/muj.2022.115662.1086
View on SCiNiTO View on SCiNiTO
Authors
Heba Selim Elshair1; Yasser Ahmed Nienaa1; Rana Ibrahim Koreen1; Noha M Elkholy email 2
1Faculty of medicine Alexandria University internal medicine department
2Department of internal medicine faculty of medicine Alexandria University
Abstract
Abstract
Background: Chronic kidney disease is a heterogeneous group of disorders involving changes in kidney structure and function. For many decades they thought that hyperuricemia causes impairment to renal function through retention of uric acid caused by impaired renal excretion. Allopurinol has been the mainstay therapy for gout and hyperuricemia associated conditions for a long time. Allopurinol has a rare but serious hypersensitivity reaction CKD patients are at higher risk of this complication. Febuxostat drug is a new potent agent which seems to be tolerable in patients involving those who develop Allopurinol sensitivity. It is a non- purine compound; It selectively inhibit xanthine oxidoreductase enzyme
Aim: To assess the renoprotective effect of Febuxostat in comparison with Allopurinol in hyperuricemic CKD patients stage 3 and 4.
Material and methods: This retrospective study included 300 patients selected from Renal outpatient clinic at Alexandria Main University Hospital and private clinics.
• 150 patients CKD stage (3,4) with hyperuricemia treated with Febuxostat renal modified dose.
• 150 patients CKD stage (3,4) with hyperuricemia treated with Allopurinol renal modified dose.
Results: In Febuxostat group than Allopurinol group at 6 months (u=8644.5, p=0.001) and 12 months (u=6316.0, p <0.001). At 6 months and 12 months data revealed no significant difference in eGFR slopes between the Febuxostat and Allopurinol groups
Keywords: Chronic Kidney Disease, Hyperuricemia, Allopurinol, Febuxostat.
Keywords
Chronic Kidney Disease; Hyperuricemia; Allopurinol; Febuxostat
Statistics
Article View: 279
PDF Download: 297